Juliana C.S. Chaves

The paper uses computational drug repurposing to identify N-acetylglucosamine as a potential therapy for CLN3 Batten disease, showing it reduces lipofuscin burden in cell models.

This paper develops a patient-derived BBB model to screen copper bis(thiosemicarbazone) complexes for Alzheimer's disease treatment, identifying CuII(dtsm) as a promising candidate with improved BBB permeability and anti-inflammatory effects.

This study shows that APOE4 increases tau levels in brain endothelial cells, reducing anti-tau antibody delivery across the blood-brain barrier in vitro.

This study demonstrates that focused ultrasound with microbubbles enhances the delivery of Aducanumab and anti-Tau antibodies across a human sporadic Alzheimer's disease blood-brain barrier model.